Please sign in using the form to the left to access these resources.
Holick Vitamin D Reprint Holick MF et al: Prevalence Of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy J Clin Endocrinol Metal. 2005;90(6):3215-3224.
One unit per package
(Limit 1 per month)
Patient Educational Materials
Please sign in using the form to the left to access these resources.
BMD Patient Primer 1 unit (each unit contains 10 brochures)
One unit per package
(Limit 100 per month)
Ask Me T-score Tear Sheet 1 unit (each unit contains 5 items)
Access our archived eMedical Forum Webcasts, which are available for your viewing at any time.
Please sign in using the form to the left to access this service.
Important Product Information
IMPORTANT PRODUCT INFORMATION:
FOSAMAX and FOSAMAX PLUS D are indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of osteoporosis, FOSAMAX and FOSAMAX PLUS D increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures).
FOSAMAX and FOSAMAX PLUS D are contraindicated in patients with esophageal abnormalities which delay esophageal emptying (eg, stricture or achalasia) and in patients unable to stand or sit upright for at least 30 minutes. Patients at increased risk of aspiration should not receive FOSAMAX oral solution. FOSAMAX and FOSAMAX PLUS D are contraindicated in patients with hypocalcemia (see WARNINGS AND PRECAUTIONS) and in patients with hypersensitivity to any component of these products. Hypersensitivity reactions including urticaria and angioedema have been reported. FOSAMAX and FOSAMAX PLUS D, like other bisphosphonates, may cause local irritation of the upper gastrointestinal mucosa.
In postmarketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the prevention and treatment of osteoporosis. The time to onset of symptoms varied from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping treatment.
COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA
FOSAMAX PLUS D is a trademark of Merck & Co., Inc.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. View the Merck/Schering-Plough privacy policy.
All other brand names are registered trademarks of Merck & Co., Inc.
MerckServices and MerckSource are registered trademarks of Merck & Co., Inc.
MerckProductServices and MerckMedicus are trademarks of Merck & Co., Inc.
Contact Us
Ask a Product-Related Question or Report an Adverse Event
Let us assist you with information and services related to Merck and its products. Get Started
Live Product Discussion About FOSAMAX® (alendronate sodium tablets)
We're ready when you are with the latest product information and resources for FOSAMAX. Begin Your Discussion
requires a 
requires a 
BMD Patient Primer
Lenticular Poster
FOSAMAX PLUS D™ (alendronate sodium/cholecalciferol)
samples are not currently available.
